Action Myoclonus-Renal Failure Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Ataxia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Atypical Inclusion-Body Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Biotin-Responsive Encephalopathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Bone Marrow failure syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aberrant hypermethylation is particularly observed in PRDM8 and this may support identification and classification of bone marrow failure syndromes.
|
26909595 |
2016 |
Confusion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Dementia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dentatorubral-Pallidoluysian Atrophy
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dyskeratosis Congenita
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
|
26909595 |
2016 |
Early-onset Lafora body disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results to date suggest that PRDM8, the early-onset Lafora body disease protein, regulates the cytoplasmic quantities of the Lafora disease enzymes.
|
22961547 |
2012 |
EPILEPSY, PROGRESSIVE MYOCLONIC, 10
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
EPILEPSY, PROGRESSIVE MYOCLONIC, 10
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Early-onset Lafora body disease.
|
22961547 |
2012 |
EPILEPSY, PROGRESSIVE MYOCLONIC, 10
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Early-onset Lafora body disease.
|
22961547 |
2012 |
EPILEPSY, PROGRESSIVE MYOCLONIC, 10
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Early-onset Lafora body disease.
|
22961547 |
2012 |
Familial Progressive Myoclonic Epilepsy
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Generalized myoclonic seizures
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hallucinations
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PRDI-BF1 and RIZ homology domain containing 8 (PRDM8) is a key regulator in neural development and testis steroidogenesis; however, its role in liver carcinogenesis remains to be investigated.
|
29572888 |
2018 |
Hyperreflexia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively.
|
30393995 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conclusion: PRDM8 as a functional tumor suppressor is frequently down-regulated in HCC.
|
29572888 |
2018 |
Lymphomatoid Papulosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively.
|
30393995 |
2019 |
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).
|
28556291 |
2017 |
May-White Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|